DCBY02 / DynamiCure Biotech - LARVOL DELTA

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: DynamiCure Biotechnology | N=108 ➔ 5 | Trial completion date: Oct 2024 ➔ Feb 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Sep 2024 ➔ Feb 2024; Review of Data, and our other compound is a better option

Enrollment change • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Trial termination • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • PD-L1

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=108 | Active, not recruiting | Sponsor: DynamiCure Biotechnology | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Monotherapy • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • PD-L1

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: DynamiCure Biotechnology | N=192 ➔ 96

Enrollment change • Metastases • Monotherapy • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • PD-L1

DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=192 | Recruiting | Sponsor: DynamiCure Biotechnology | N=96 ➔ 192

Enrollment change • Metastases • Monotherapy • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • PD-L1

DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced Cancers (GlobeNewswire) - "DynamiCure...today announced that it has dosed the first patients in its Phase 1 clinical trial evaluating the safety and anti-tumor activity of the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers."

Trial status • Oncology • Solid Tumor

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: DynamiCure Biotechnology | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • PD-L1

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Not yet recruiting | Sponsor: DynamiCure Biotechnology

Monotherapy • New P1 trial • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • PD-L1

DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development (GlobeNewswire) - "DynamiCure...announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to advance the first monoclonal antibody candidate from the company’s DC-6001 anti-CD93 development program into a Phase 1 study (NCT05496595). The study is designed to evaluate the safety and efficacy of DCBY02 in adult patients with a wide range of advanced cancers....The Phase 1 program consists of two parts: a dose-escalation phase (Part 1) to determine a recommended Phase 2 dose (RP2D), followed by a dose-expansion phase (Part 2) at the RP2D....DynamiCure plans to submit the IND for the second monoclonal antibody from the DC-6001 program, DCSZ11, in the fourth quarter of 2022."

IND • New P1 trial • Oncology • Solid Tumor